Table 3.
Univariate and multivariate analysis for NRM
| Univariate analysis | Multivariate analysis | |||
|---|---|---|---|---|
| Patient and Graft Characteristics |
HR (95%CI) | p value | HR (95%CI) | p value |
| Sex | ||||
| Male | Ref. | 0.12 | - | |
| Female | 1.4 (0.9–2.1) | |||
| D/R gender combination | ||||
| Female to Male | Ref. | 0.14 | - | |
| Other | 1.6 (0.9–2.9) | |||
| Age (years) | ||||
| < 40 | Ref. | 0.02 | Ref. | 0.12 |
| ≥40 | 2.3 (1.1–4.8) | 1.8 (0.9–4) | ||
| Donor | ||||
| Related donor | Ref. | 0.06 | Ref. | 0.22 |
| Non-related donor | 1.5 (1–2.4) | 1.4 (0.8–2.2) | ||
| HLA compatibility | ||||
| Identical | Ref. | 0.04 | Ref. | 0.15 |
| Non-identical | 1.6 (1–2.4) | 1.4 (0.9–2.5) | ||
| Diagnosis | ||||
| Acute myeloid leukemia | Ref. | 0.47 | - | |
| Myelodisplastic syndrome | 1.2 (0.8–1.8) | |||
| Transplant year | Ref. 1.0 (0.9–1.0) |
0.2 | - | |
| HCT-CI | ||||
| 0 | Ref. | < 0.001 | Ref. | 0.002 |
| 1–2 | 1.2 (0.6–2.5) | 1.3 (0.6–2.6) | ||
| ≥3 | 2.8 (1.5–5.3) | 2.5 (1.4–4.8) | ||
| HCT-CI/age | ||||
| 0 | Ref. | < 0.001 | Ref. | < 0.001 |
| 1–2 | 2.7 (0.4–20.5) | 2.4 (0.3–18) | ||
| 3–4 | 5.8 (0.8–42.3) | 5.1 (0.7–37.8) | ||
| ≥5 | 10 (1.4–72.7) | 8.3 (1.1–62.1) | ||
| Conditioning regimen | ||||
| TBI based | Ref. | 0.01 | Ref. | 0.5 |
| Chemo based | 1.9 (1.1–3) | 0.8 (0.5–1.4) | ||
| CD34+ × 106/kg dose | ||||
| < 7.6×106/kg | Ref. | 0.27 | - | |
| ≥ 7.6×106/kg | 0.8 (0.5–1.2) | |||
| CD34+ selection method | ||||
| Clinimacs ® | Ref. | 0.29 | - | |
| OTHER | 1.3 (0.8–2) | |||
Abbreviations: NRM, non-relapse mortality; OS, overall survival, CRFS Chronic GVHD-Free, Relapse-Free Survival; D/R, donor/recipient; HCT-CI, Hematopoietic Cell Transplantation Comorbidity Index.